Leukocyte-Adhesion Deficiency Syndrome

This is a rare condition where your body's white blood cells can't stick properly to the walls of blood vessels. This makes it hard for them to get to places where they are needed, like fighting infections. It's caused by a missing protein that helps white blood cells stick.

Condition

What people with Leukocyte-Adhesion Deficiency Syndrome report

Every report comes from a Lived member, sent anonymously.

Have you had Stem Cell Transplant for Leukocyte-Adhesion Deficiency Syndrome?

NameHow it went

About Leukocyte-Adhesion Deficiency Syndrome

What It Is

Leukocyte adhesion deficiency (LAD) is a rare inherited immune disorder in which white blood cells cannot leave the bloodstream to fight infection. Normally, white cells (leukocytes) stick to the wall of a blood vessel near an infection or wound and then squeeze through it into the tissue. In LAD, they lack a working adhesion protein, so they circulate in large numbers but cannot reach the place where they are needed. The result is serious bacterial and fungal infections that begin in infancy, most often in the skin, the lining of the mouth and nose, the lungs and the gut. One of the earliest clues is an umbilical cord stump that is slow to fall off (often three weeks or later) or becomes infected. Infections typically form little or no pus, wounds heal slowly, and severe gum disease commonly leads to loss of baby and adult teeth. There are three recognized types. LAD type I is by far the most common and is what this page mainly describes. It is classed as severe or moderate depending on how much of the adhesion protein is present and how serious the infections have been. LAD type II also causes slowed growth and developmental delay, and LAD type III adds a bleeding tendency to the infections.

Causes & Risk Factors

LAD is caused by changes in a single gene and is present from birth. In LAD type I, the affected gene is ITGB2, which carries instructions for CD18, part of a family of adhesion proteins called beta-2 integrins. LAD type II involves a gene needed to attach a sugar (fucose) to proteins on white cells, and LAD type III involves a protein called kindlin-3 that switches the adhesion proteins on. All three types are inherited in an autosomal recessive pattern: a child is affected only when they receive a nonworking copy of the gene from each parent. Parents who each carry one copy are usually healthy, and each of their children has a one in four chance of being affected. Nothing a parent did during pregnancy causes LAD, and infections are a consequence of the condition rather than its cause. LAD type I affects roughly one in a million people worldwide.

How It's Diagnosed

LAD is usually suspected in a baby or young child with delayed cord separation, repeated serious infections without pus, poor wound healing or early severe gum disease. A routine blood count often shows a very high white cell count, even between infections, because the cells are trapped in the bloodstream. The key test is flow cytometry, a blood test that measures how much of the adhesion proteins (CD18 and the related CD11a and CD11b) sit on the surface of white cells. In severe LAD type I, almost none is present, usually under 2 percent of normal. In moderate LAD type I, some is present, roughly 2 to 30 percent. Doctors also weigh the clinical picture: a single life-threatening infection is enough to treat the disease as severe, whatever the test shows. Genetic testing of the ITGB2 gene confirms the diagnosis, which matters before transplant or gene therapy and allows testing of siblings and future pregnancies. Babies born into a family with a known history can be tested soon after birth, before infections begin. LAD types II and III need different specialized tests, including platelet function studies for type III.

Treatment Options

Care is led by a clinical immunology team, usually at a specialist center. For severe LAD type I, a stem cell transplant (also called a bone marrow transplant) is the established treatment that can correct the disease. Blood-forming stem cells from a donor, ideally a matched brother or sister, replace the child's own, so the new white cells carry working adhesion proteins. Without this kind of definitive treatment, severe LAD carries a high risk of death in childhood. Transplant is demanding: it involves chemotherapy beforehand, weeks in hospital and risks such as graft failure and graft-versus-host disease (when donor immune cells attack the recipient's body). It works best when done before serious infections take hold or once active infections are under control, and preparation commonly takes a few months. In 2026 the US Food and Drug Administration (FDA) granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for LAD. It is for children with severe LAD type I who do not have a matched sibling donor. The child's own stem cells are collected, given a working copy of the ITGB2 gene in a laboratory and returned by infusion after chemotherapy. Because it uses the child's own cells, no donor is needed. Approval was based on restored adhesion-protein levels in a small study, and longer-term benefit is still being confirmed. Until definitive treatment, and for people with moderate disease who may not need it, supportive care aims to prevent and control infection. This includes daily preventive antibiotics, prompt and often prolonged treatment of infections (frequently intravenous and in hospital), routine vaccinations, careful skin and dental hygiene, and sometimes surgery to remove infected tissue. Preventive antibiotics reduce but do not eliminate infections. Some children develop severe inflammation of the skin or bowel, and ustekinumab (Stelara), an injectable biologic medicine that blocks inflammation signals, has been used for this. LAD type II has a distinct option: oral fucose supplements have improved the immune defect in some, but not all, people.

What to Expect

Severe LAD type I is a serious disease of infancy and early childhood. Without transplant or gene therapy, children typically face several severe infections each year, frequent and lengthy hospital stays and a shortened life. Surviving past age two does not mean the disease has become milder. After a successful transplant or gene therapy, white cells can reach infections normally, and families can move toward more ordinary daily routines, although recovery and follow-up take months and long-term monitoring continues. People with moderate LAD type I often live into adulthood with antibiotics and careful management. Gum disease, tooth loss, slow-healing skin ulcers and scarring are common, so regular dental care is part of daily life. Moderate disease can worsen over time, so specialists reassess it periodically and may revisit transplant. For families, the burden is substantial: frequent appointments, infection precautions, financial strain and uncertainty. Specialists advise against long-term social isolation as a strategy. Genetic counseling helps relatives understand their own carrier status and options for future pregnancies, and siblings may be tested as possible donors.

When to Seek Help

Ask for an immunology assessment if a baby's cord stump has not separated by about three weeks or becomes red and infected, or if a child has repeated serious infections, wounds that heal poorly without pus, or severe gum disease and early tooth loss. For anyone already diagnosed, contact the immunology team right away for a fever, skin or gum redness and swelling that is spreading, a cough with fever, belly pain with diarrhea, or an infant who is feeding poorly or unusually sleepy. Because pus does not form, infections can look mild while they are becoming serious, and many need prompt intravenous antibiotics in hospital. A child with LAD who has trouble breathing, is hard to wake or seems very unwell needs emergency care.

Questions to Ask Your Doctor

  1. 1.Is this severe or moderate LAD type I, and what test results and history support that?
  2. 2.Does our family have a matched sibling donor, and how do transplant and gene therapy compare for my child?
  3. 3.Which signs of infection should prompt a call, and what is the plan if my child needs to be seen urgently?
  4. 4.What can we do at home and with dental care to lower the risk of infection without isolating our child?
  5. 5.Should other family members or future pregnancies be tested, and can we meet a genetic counselor?

Last reviewed • Oct 2026

Educational content, not medical advice.